Literature DB >> 9018461

Gastrointestinal features of scleroderma.

R W Sjogren1.   

Abstract

Gastrointestinal involvement occurs in most patients with systemic sclerosis and is subclinical in about one third. Early pathology is characterized by vasculopathy, resulting in tissue ischemia and progressive dysfunction. Noninvasive esophageal studies using semisolid bolus scintigraphy are sensitive but lack specificity. Long-term treatment of reflux with high-dose proton pump inhibitors appears safe and effective for symptom relief and may prevent recurrence of esophagitis and stricture. Dyspepsia may result from gastroparesis and antral distension. Gastric antral vascular ectasia is a vascular manifestation, and bleeding may be controlled endoscopically. Prokinetic agents effective in pseudoobstruction include metoclopramide, domperidone, cisapride, octreotide, and erythromycin. Patients with intestinal neuropathy or response to bolus octreotide are more probable long-term responders. The combination of octreotide and erythromycin may be particularly effective in systemic sclerosis. The combination of cisapride and erythromycin may cause serious cardiac arrhythmia and is contraindicated. Omeprazole may predispose to small intestinal bacterial overgrowth. Malabsorption not responding to antibiotic therapy should be investigated with small-bowel biopsy to rule out more unusual causes. Pneumatosis cystoides intestinalis may be due to excessive hydrogen production by intestinal bacteria altering the partial pressure of nitrogen in the intestinal wall. In selected cases, surgery for intestinal failure is an option with resection or bypass of affected segments or placement of enterostomy tubes for feeding or decompression. Careful preoperative characterization of intestinal segments is required.

Entities:  

Mesh:

Year:  1996        PMID: 9018461     DOI: 10.1097/00002281-199611000-00012

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  32 in total

1.  Severe gastrointestinal disease in very early systemic sclerosis is associated with early mortality.

Authors:  Nicolas Richard; Marie Hudson; Mianbo Wang; Geneviève Gyger; Susanna Proudman; Wendy Stevens; Mandana Nikpour; Murray Baron
Journal:  Rheumatology (Oxford)       Date:  2019-04-01       Impact factor: 7.580

Review 2.  Evidence-based management of rapidly progressing systemic sclerosis.

Authors:  Dinesh Khanna; Christopher P Denton
Journal:  Best Pract Res Clin Rheumatol       Date:  2010-06       Impact factor: 4.098

3.  Gastric slow waves, gastrointestinal symptoms and peptides in systemic sclerosis patients.

Authors:  T A McNearney; H S Sallam; S E Hunnicutt; D Doshi; D E Wollaston; M D Mayes; J D Z Chen
Journal:  Neurogastroenterol Motil       Date:  2009-06-30       Impact factor: 3.598

4.  The validity and reliability study of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract (UCLA SCTC GIT) 2.0 questionnaire for the Turkish society.

Authors:  Yaşar Murat Taş; Gözde Derviş Hakim; Pembe Keskinoğlu; Gökçe Kenar; Handan Yarkan; Berrin Zengin; Gerçek Can; Fatoş Önen; Nurullah Akkoç; Merih Birlik; Mesut Akarsu
Journal:  Turk J Gastroenterol       Date:  2019-03       Impact factor: 1.852

Review 5.  Review article: pathogenesis and clinical manifestations of gastrointestinal involvement in systemic sclerosis.

Authors:  S Kumar; J Singh; S Rattan; A J DiMarino; S Cohen; S A Jimenez
Journal:  Aliment Pharmacol Ther       Date:  2017-02-09       Impact factor: 8.171

6.  Role of muscarinic-3 receptor antibody in systemic sclerosis: correlation with disease duration and effects of IVIG.

Authors:  Sumit Kumar; Jagmohan Singh; Ramalinga Kedika; Fabian Mendoza; Sergio A Jimenez; Erik S Blomain; Anthony J DiMarino; Sidney Cohen; Satish Rattan
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-05-12       Impact factor: 4.052

7.  Gastrointestinal manifestations in Hungarian scleroderma patients.

Authors:  Szilvia Szamosi; Zoltán Szekanecz; Gabriella Szucs
Journal:  Rheumatol Int       Date:  2006-06-13       Impact factor: 2.631

8.  Profile of gastrointestinal involvement in patients with systemic sclerosis.

Authors:  T Schmeiser; P Saar; D Jin; M Noethe; A Müller; N Soydan; P D Hardt; C Jaeger; O Distler; E Roeb; R G Bretzel; U Müller-Ladner
Journal:  Rheumatol Int       Date:  2011-07-19       Impact factor: 2.631

Review 9.  Measuring response in the gastrointestinal tract in systemic sclerosis.

Authors:  Dinesh Khanna; Vivek Nagaraja; Heather Gladue; William Chey; Mark Pimentel; Tracy Frech
Journal:  Curr Opin Rheumatol       Date:  2013-11       Impact factor: 5.006

10.  Reliability and validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument.

Authors:  Dinesh Khanna; Ron D Hays; Paul Maranian; James R Seibold; Ann Impens; Maureen D Mayes; Philip J Clements; Terri Getzug; Nihal Fathi; Amber Bechtel; Daniel E Furst
Journal:  Arthritis Rheum       Date:  2009-09-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.